In this episode of Future of Drug Discovery, we speak with Louise Liu, Founder and CEO of Hill Research.
The statistical programming behind an FDA submission is one of the slower steps in clinical development. Eight programmers, six months and eight million dollars is roughly what it takes to produce the data package for a single Phase 3 trial.
Hill Research is doing that work with one person, in 90 minutes, with the help of generative AI.
In this conversation, we get into how the technology works, what the FDA thinks about the use of AI in submissions, the accountability question pharma executives are asking, and what the next decade of clinical development could look like if the rest of the pipeline catches up.
Be sure to like, rate and review the podcast if you enjoyed this episode!
Podden och tillhörande omslagsbild på den här sidan tillhör
Murat Tunaboylu. Innehållet i podden är skapat av Murat Tunaboylu och inte av,
eller tillsammans med, Poddtoppen.
